Stevanato Group at Achema to present demo of its Vision Robot Unit for visual inspection of parenteral drugs

From inspection to palletizing, the company's modular solutions offer the pharma world the right degree of flexibility to land on the market in a scalable manner

Stevanato Group S.p.A. (NYSE: STVN) a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, will be at ACHEMA August 22-26 to present its innovative visual inspection system, such as VRU, along with other assembly and packaging solutions.

At Booth H99 in the Hall 3.0 the Company will feature a demo of the VRU, a robotic system for visual inspection of glass containers and parenteral drugs, which leverages artificial intelligence principles to raise performance and efficiency levels in production processes of pharmaceutical companies
Stevanato Group's innovative robotic unit combines the flexibility typical of manual inspection with the efficiency and repeatability of automation. Designed on the principles of artificial intelligence, the VRU module is capable of automatically inspecting, without human intervention, cosmetic and particulate defects in inspected drugs and glass containers - vials, syringes, cartridges. The system is also ideal for a wide range of applications in the pharmaceutical manufacturing landscape, including biotechnology products such as monoclonal antibodies (mAbs), vaccines, and lyophilized drugs.

Along with the VRU, the Company will be present at Achemawith other digital innovations developed to enable pharmaceutical companies to increase production performance and quality while reducing time-to-market. Examples include: the Artificial Intelligence platform applied to visual inspection, the Digital Twin to make virtual copies of assembly machines and shorten set-up times, and finally, data collection tools to gather useful information to improve performance.

At Achema, Stevanato Group will also present to pharmaceutical companies its modular, scalable and flexible assembly solutions. The presence of a wide range of devices on the Pharma market makes the versatility and modularity of the machines essential to adapt to wide-ranging production scenarios. Embracing the challenge of scalability, Stevanato Group empowers pharmaceutical companies and contract manufacturers with a modular approach that can optimize production, ensure flexibility and allow customers to accelerate the stages between the laboratory and the market.

About Stevanato Group

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value-added solutions to clients. To learn more, visit: www.stevanatogroup.com.

Contact

Media
Stevanato Group: media@stevanatogroup.com
Rebecca Rossetti/Arianna Cusolito: stevanatoita@teamlewis.com

Investor Relations
Lisa Miles: lisa.miles@stevanatogroup.comName email

Forward-Looking Statements

This press release may include forward-looking statements. The words "expects", “planned”, "intended", “believe”, and similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the investments the Company expects to receive, the expansion of manufacturing capacity, the Company’s plans regarding its presence in the U.S. market, business strategies, the Company’s capacity to meet future market demands and support preparedness for future public health emergencies, and results of operations. The forward-looking statements in this press release are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of regulators and other factors such as the Company's ability to continue to obtain financing to meet its liquidity needs, changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions. In particular, the Company may determine not to conduct a registered initial public offering in the time frame that it currently expects or at all, due to a number of potential important factors, including conditions in the U.S. capital markets, negative global economic conditions, potential negative developments in the Company’s business, or unfavorable or regulatory developments. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the company assumes no obligation to update any such forward-looking statements.